Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

Abstract Background The live attenuated tetravalent dengue vaccine (CYD-TDV) is licensed using a 0-, 6- and 12-month schedule in dengue-endemic areas. An effective shorter schedule may provide more rapid, optimal protection of targeted populations during vaccine campaigns in dengue-endemic countries...

Full description

Bibliographic Details
Main Authors: Judith Kirstein, William Douglas, Manoj Thakur, Mark Boaz, Thomas Papa, Anna Skipetrova, Eric Plennevaux
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Infectious Diseases
Subjects:
Dengue
Live attenuated tetravalent dengue vaccine
Yellow fever
Vaccination schedule
Online Access:http://link.springer.com/article/10.1186/s12879-018-3389-x

Internet

http://link.springer.com/article/10.1186/s12879-018-3389-x

Similar Items